Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The effectiveness of neoadjuvant therapy in esophageal cancer (EC) treatment is still a subject of debate.
Aim: To compare the clinical efficacy and toxic side effects between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) for locally advanced EC (LAEC).
Methods: A comprehensive search was conducted using multiple databases, including PubMed, EMBASE, MEDLINE, Science Direct, The Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Journal Database, and Chinese Biomedical Literature Database Article. Studies up to December 2022 comparing nCRT and nCT in patients with EC were selected.
Results: The analysis revealed significant differences between nCRT and nCT in terms of disease-free survival. The results indicated that nCRT provided better outcomes in terms of the 3-year overall survival rate (OSR) [odds ratio (OR) = 0.95], complete response rate (OR = 3.15), and R0 clearance rate (CR) (OR = 2.25). However, nCT demonstrated a better 5-year OSR (OR = 1.02) than nCRT. Moreover, when compared to nCRT, nCT showed reduced risks of cardiac complications (OR = 1.15) and pulmonary complications (OR = 1.30).
Conclusion: Overall, both nCRT and nCT were effective in terms of survival outcomes for LAEC. However, nCT exhibited better performance in terms of postoperative complications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824113 | PMC |
| http://dx.doi.org/10.4251/wjgo.v16.i1.214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation for Esophageal Adenocarcinoma: A National Cancer Database Analysis.
Ann Surg Oncol
August 2025
Department of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA.
Background: While neoadjuvant chemoradiation (NCRT) has been the acceptable standard of care for esophageal adenocarcinoma (EAC), there has been a paradigm shift based on recent trials showing neoadjuvant chemotherapy (NCT) as being either equivalent or superior to NCRT. We sought to examine the outcomes of NCT versus NCRT in esophageal cancer.
Methods: Utilizing the National Cancer Database, we identified esophagectomy patients with EAC who underwent multi-agent NCT versus multi-agent NCRT.
Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.
BMC Cancer
August 2025
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijizhuang, China.
Background: This study aimed to compare the efficacies of neoadjuvant chemoradiotherapy (NCRT), chemotherapy (NCT), and chemoimmunotherapy (NCIT) in patients with locally advanced esophageal squamous cell carcinoma (LAESCC). The primary objective was to assess the overall survival (OS) among the three treatment groups.
Methods: A retrospective cohort of 625 patients treated at the Fourth Hospital of Hebei Medical University between 2016 and 2022 was analyzed.
Neoadjuvant Treatment and Postoperative Complications After Surgery for Esophageal Cancer: A Population-Based, Nationwide Study in Finland.
Ann Surg Oncol
August 2025
Surgery Research Unit, Oulu University Hospital and University of Oulu, Oulu, Finland.
Background: The role of neoadjuvant treatment and its modalities in the risk of complications after esophagectomy in national practice is unclear. The aim of this study was to compare postoperative complications after neoadjuvant treatment (nT) and upfront surgery (US), neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT), and to assess the effect of complications from neoadjuvant treatment in surgical risk.
Patients And Methods: All patients undergoing esophagectomy for esophageal cancer in Finland in 2005-2016 were included.
Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study.
BMC Cancer
August 2025
Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
Background: As neoadjuvant therapies become increasingly crucial in the management of esophageal squamous cell carcinoma (ESCC), improving local control, R0 resection rates, and overall survival, determining the optimal neoadjuvant strategy remains a priority. This study retrospectively assesses the efficacy and safety of neoadjuvant immunochemotherapy (NICT), chemoradiotherapy (NCRT), and chemotherapy (NCT) in operable ESCC.
Methods: Analyzing preoperative clinical data from resectable ESCC patients treated with NICT, NCRT, or NCT at Shandong Cancer Hospital from January 2018 to August 2022, we focused on surgical complications, pathological responses, and survival outcomes.
Neoadjuvant chemotherapy versus long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of 5,168 cases.
Front Oncol
June 2025
Department of Gastrointestinal Surgery, The People's Hospital of Leshan, Leshan, China.
Background: Long-course neoadjuvant chemoradiotherapy (Lc-NCRT) is the conventional treatment for locally advanced rectal cancer (LARC). It improves R0 resection rate and reduces local recurrence rate, but it cannot improve long-term oncological outcomes. It also causes several radiotherapy-related side effects.
View Article and Find Full Text PDF